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after RT, is probably due to the smaller sample size. No 
significant differences according to type and duration of HT 
were observed. Newer strategies to reduce the negative 
impact on QoL of HT and further analysis based on PC-
specific assessment tools appear to be justified. 
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Purpose/Objective: To report 5-year clinical outcomes and 
late toxicity in prostate cancer patients (pts) treated with 
Image Guided Radiotherapy (IGRT) Moderate 
Hypofractionated Simultaneous integrated boost (SIB) by 
Tomotherapy in a Phase I-II study. 
Materials and Methods: 211 pts ( 78 low- risk[LR], 53 
intermediate- risk [IR] and 80high-risk[HiR]) were treated 
between 2005 and 2011. IR and HiR pts received 51,8 Gy on 
pelvic lymph-nodes (LN) and concomitant SIB to prostate up 
to 74,2Gy in 28 fr; LR pts were treated to the prostate to 
71,4Gy in 28fr. Androgen deprivation (AD) was delivered to 
33%,43% and 88% of LR/IR/HiR pts for a median time of 6, 12 
and 34 months (m) respectively. The gastrointestinal (GI) and 
genitourinary (GU) late toxicities were recorded according to 
the RTOG scoring system. Biochemical relapse free (bRFS) 
survival (Phoenix definition), cancer-specific (CCS) and 
overall survival (OS) actuarial curves were assessed. Selected 
clinical/dosimetry variables were tested as potential 
predictors of GI /GU toxicity and of BCR/CCS/OS (Cox test) . 
Results: Median follow was 60m. The 5-year incidence of late 
toxicity was: GU≥ 2 : 20.2 %; GU ≥G3 : 5.9% ; GI≥2 : 17%; 
GI≥3: 6,3%.The prevalence at the last control was: GU ≥G2: 
7.1%, ≥G3: 1.9% ; GI ≥G2:5.2%, ≥G3: 1.9%. Best predictors of 
≥G3 GU and GI late toxicity were GU acute toxicity≥G2 ( [HR] 
:4.9) and previous surgery (HR:3.4) respectively. The overall 
5-year bRFS was 93.7% (LR: 94.6%; IR: 96.2%; HiR: 91.1%); OS 
was 88.6% ( LR:90.5%; IR: 87.4%; HR: 87%) and CSS was 97.5% 
(LR: 98.7%;IR:95%;HiR: 94.3%). AD and class risk were not 
correlated with bRFS/OS/CSS. 
Conclusions: The combination of pelvic LN irradiation and 
high dose to the prostate (EQD2=88Gy) delivered with daily 
image-guided, intensity-modulated, moderate 
hypofractionation resulted in an excellent 5-year outcome, 
even in IR/HiR patients. The 5-year toxicity profile was 
acceptable with G3 incidences around 6%. The drastically 
reduced prevalence at the last follow-up for both ≥G2 and 
≥G3 toxicities shows that symptoms were recovered in most 
patients. 
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Purpose/Objective: Patient reported outcomes (PRO) are 
important in the assessment of morbidity following treatment 
for prostate cancer, and may detect more late toxicity from 
radiotherapy than clinician reported outcomes. The CHHiP 
trial (Conventional or Hypofractionated High dose intensity 
modulated radiotherapy in Prostate cancer) randomised 
patients with early or intermediate risk localised prostate 
cancer to a standard arm of 74Gy/37f versus experimental 
arms of 60Gy/20f or 57Gy/19f and included a PRO substudy.  
Materials and Methods: PROs of overall bowel bother 
(primary endpoint) and overall urinary bother (key secondary 
endpoint) were assessed as single items within UCLA-PCI and 
EPIC-50 quality of life instruments. These were completed at 
baseline, pre-radiotherapy (pre-RT), 10 weeks, 6, 12, 18 and 
24 months post radiotherapy. All tests were conducted 
between the control group and each experimental arm. A 
significance level of 0.001 was used with 99% confidence 
intervals to allow for multiple testing. A difference in overall 
bowel or urinary bother score at 24 months was tested using 
the chi-squared test for trend. Kaplan-Meier methods were 
used to assess time to 'small' bother, with differences 
between arms assessed using the log-rank test. The odds of 
an increase in bother from pre-RT to 24 months were 
modelled using ordered logistic regression. 
Results: 2011 patients consented to the PRO substudy. 
Return rates were 1659 patients (82.5%) pre-RT and 1444 
(71.8%) at 24 months. 139 PRO pre-RT and 172 PRO at 24 
months dated outside pre-determined acceptable time 
intervals were excluded from fixed timepoint analyses A 
temporary increase in any bother was seen at 10 weeks 
indicative of acute radiation toxicity (from 408/1498 (27.2%) 
pre-RT to 741/1308 (56.7%) at 10 weeks). Cross-sectional 
analysis at 24 months showed no difference between 
treatment arms (table 1). 
 
 
 
No differences were seen in time to small overall bowel 
bother (74Gy vs 60Gy: hazard ratio (HR) 1.11 99% CI: (0.85-
1.46), p=0.32; 74Gy vs 57Gy: HR 0.97 (0.73-1.28), p=0.77) or 
small overall urinary bother (74Gy vs 60Gy: HR 0.99 (0.74-
